Pharmacokinetics of tulathromycin in healthy and neutropenic mice challenged intranasally with lipopolysaccharide from Escherichia coli.

Antimicrobial Agents and Chemotherapy
N VillarinoT Martín-Jiménez

Abstract

Tulathromycin represents the first member of a novel subclass of macrolides, known as triamilides, approved to treat bovine and swine respiratory disease. The objectives of the present study were to assess the concentration-versus-time profile of tulathromycin in the plasma and lung tissue of healthy and neutropenic mice challenged intranasally with lipopolysaccharide (LPS) from Escherichia coli O111:B4. BALB/c mice were randomly allocated into four groups of 40 mice each: groups T-28 (tulathromycin at 28 mg/kg of body weight), T-7, T7-LPS, and T7-LPS-CP (cyclophosphamide). Mice in group T-28 were treated with tulathromycin at 28 mg/kg subcutaneously (s.c.) (time 0 h). The rest of the mice were treated with tulathromycin at 7 mg/kg s.c. (time 0 h). Animals in dose groups T-7-LPS and T7-LPS-CP received a single dose of E. coli LPS intranasally at -7 h. Mice in group T7-LPS-CP were also rendered neutropenic with cyclophosphamide (150 mg/kg intraperitoneally) prior to the administration of tulathromycin. Blood and lung tissue samples were obtained from 5 mice from each dose group at each sampling time over 144 h after the administration of tulathromycin. There were not statistical differences in lung tissue concentrations among gr...Continue Reading

References

Jul 1, 1992·Antimicrobial Agents and Chemotherapy·E ValléeE Bergogne-Bérézin
Jun 1, 1991·Antimicrobial Agents and Chemotherapy·E Azoulay-DupuisJ J Pocidalo
May 1, 1991·The Journal of Antimicrobial Chemotherapy·W A CraigS C Ebert
Jun 1, 1990·Antimicrobial Agents and Chemotherapy·R P Gladue, M E Snider
Nov 1, 1987·The Journal of Antimicrobial Chemotherapy·M B CarlierP M Tulkens
Jan 1, 1995·The Journal of Antimicrobial Chemotherapy·A PascualE J Perea
Apr 1, 1995·Pulmonary Pharmacology·E Bergogne-Berezin
Oct 24, 1996·European Journal of Pharmacology·J P MontenezM P Mingeot-Leclercq
Mar 10, 1997·Journal of Immunological Methods·R J SzarkaR H Smith
May 17, 2001·Antimicrobial Agents and Chemotherapy·G L Mandell, E Coleman
Nov 17, 2001·International Journal of Antimicrobial Agents·W L Hand, D L Hand
Nov 21, 2001·Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.]·J A NemzekD G Remick
Jul 11, 2002·Microbes and Infection·Martine CaroffNicole Haeffner-Cavaillon
Sep 10, 2002·Bioorganic & Medicinal Chemistry Letters·Michael A LetavicSheryl L Santoro
Dec 25, 2003·Antimicrobial Agents and Chemotherapy·Nasia SafdarW A Craig
Apr 15, 2004·Journal of Agricultural and Food Chemistry·Diana GálerMarcus A Nowakowski
Aug 13, 2004·Journal of Veterinary Pharmacology and Therapeutics·H A BenchaouiS J Sunderland
May 27, 2005·Antimicrobial Agents and Chemotherapy·Martina BosnarMichael J Parnham
Oct 19, 2006·The Veterinary Journal·Monica VennerErich Klug
Feb 3, 2007·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Eberhard ScheuchWerner Siegmund
Feb 14, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Annick SeithelJörg König

❮ Previous
Next ❯

Citations

Nov 26, 2013·The Veterinary Journal·Nicolas VillarinoTomás Martín-Jiménez
Aug 8, 2015·Food Additives & Contaminants. Part A, Chemistry, Analysis, Control, Exposure & Risk Assessment·Tomasz BladekAnna Gajda
Apr 15, 2015·Antimicrobial Agents and Chemotherapy·Nicolas VillarinoNathan W Schmidt
Oct 17, 2012·Journal of Veterinary Pharmacology and Therapeutics·N VillarinoT Martín-Jiménez
Jun 12, 2019·Journal of Veterinary Pharmacology and Therapeutics·Joe S SmithRonald W Griffith
Oct 15, 2013·Journal of Veterinary Pharmacology and Therapeutics·N VillarinoT Martín-Jiménez
Nov 22, 2014·Journal of Veterinary Pharmacology and Therapeutics·L Dieste-PérezP M Muñoz

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.